{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The investigators will study three dose levels using the 3+3 algorithm. MTD will be assess with dose limiting toxicities (DLTs) based solely on adverse events that occur during cycle 1.","groups":[{"description":"Combination of cabozantinib, carfilzomib and dexamethasone Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16 Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG000","title":"Treatment"}],"paramType":"NUMBER","populationDescription":"Only subjects that were dosed are included in this analysis","reportingStatus":"POSTED","timeFrame":"1 cycle (approximately 28 days)","title":"Maximum Tolerated Dose (MTD) of Daily Cabozantinib Given","type":"PRIMARY","unitOfMeasure":"mg"}